Lineage Cell Therapeutics (LCTX) Retained Earnings (2010 - 2026)

Lineage Cell Therapeutics has reported Retained Earnings for 17 years, with the latest figure at -$471.8 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 17498.28% year-over-year to -$471.8 million; the trailing twelve-month figure through Mar 2026 stood at -$471.8 million (down 17498.28% YoY), and the FY2025 full-year result was -$467.0 million, down 15.75% from the prior year.
• Retained Earnings for Q1 2026 stood at -$471.8 million, down from -$467.0 million in the prior quarter.
• The five-year high for Retained Earnings was -$2.6 million in Q2 2023, with the low at -$471.8 million in Q1 2026.
• Historically, Retained Earnings has averaged -$235.5 million across 5 years, with a median of -$357.0 million in 2022.
• Annual changes were most pronounced in 2025 — Retained Earnings soared 99.32% — and 2026, when it plunged 17498.28%.
• Lineage Cell Therapeutics' Retained Earnings stood at -$3.6 million in 2022, then grew by 14.09% to -$3.1 million in 2023, then slumped by 13050.75% to -$403.5 million in 2024, then declined by 15.75% to -$467.0 million in 2025, then decreased by 1.03% to -$471.8 million in 2026.
• The last three Retained Earnings figures came in at -$471.8 million (Q1 2026), -$467.0 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.